Abstract 731: Integrating ctDNA and FDG-PET dynamics to predict pathological response following neoadjuvant systemic therapy in stage III melanoma
Wei Yen Chan(The University of Sydney), Helen Rizos(Macquarie University), George Au‐Yeung(The University of Melbourne), Russell J. Diefenbach(The University of Sydney), Georgina V. Long(Westmead Hospital), Robyn P.M. Saw(Melanoma Institute Australia), Matteo S. Carlino(The University of Sydney), Ashleigh Stewart(The University of Sydney), Richard A. Scolyer(University of California, San Francisco), Edward C. Hsiao(Gladstone Institutes), Andrew J. Spillane(Melanoma Institute Australia), Jenny Lee(Blacktown & Mount Druitt Hospital), Maria Gonzalez(The University of Sydney), Li Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Sydney Ch'ng(Melanoma Institute Australia), Alexander M. Menzies(The University of Sydney)
Cited by 0
Related Papers
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
|The Lancet Oncology|2018|658
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656